Cancer Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Indication Type (Prostate Cancer, Melanoma, Bladder Cancer, Cervical Cancer), By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines), By Technology Type (Recombinant Cancer Vaccines, Whole-Cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines), By Region, Competition Forecast

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Summary

Report Description

Forecast Period

2024-2028

Market Size (2023)

USD 7.55 Billion

CAGR (2023-2028)

8.87%

Fastest Growing Segment

Recombinant Vaccines

Largest Market

North America


Market Overview

Global Cancer Vaccines Market has valued at USD 7.55 Billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.87% through 2028. A cancer vaccine is a type of immunotherapy that aims to stimulate the immune system to recognize and attack cancer cells. Unlike traditional vaccines that prevent infectious diseases, cancer vaccines are designed to treat or prevent cancer by leveraging the body's own immune response. The concept behind cancer vaccines is to present the immune system with specific molecules or antigens found on the surface of cancer cells. These antigens are often unique to cancer cells or are more abundant on cancer cells compared to normal cells. By exposing the immune system to these antigens, the goal is to prime immune cells to identify and destroy cancer cells while sparing healthy cells. The success of immunotherapies, including immune checkpoint inhibitors and CAR-T cell therapies, has generated interest and confidence in the potential of cancer vaccines. These advancements have highlighted the role of the immune system in targeting cancer cells, driving further research and investment in cancer vaccines. Advances in genomics, proteomics, and bioinformatics have enabled a deeper understanding of tumor biology and the identification of potential vaccine targets. These technological innovations have accelerated the discovery and development of cancer vaccines. The concept of combining different treatment modalities, such as vaccines with immune checkpoint inhibitors or chemotherapy, has gained traction. Combination therapies have the potential to enhance treatment efficacy and overcome resistance mechanisms. Various global health organizations and initiatives have highlighted the importance of cancer prevention and treatment. These initiatives contribute to increased awareness and funding for cancer vaccine research and development.

Key Market Drivers

Growing Demand of Immune Checkpoint Inhibitors

Immune checkpoint inhibitors are a class of cancer immunotherapy drugs that have revolutionized the treatment of various types of cancer. These drugs work by targeting specific molecules on immune cells and cancer cells to enhance the immune system's ability to recognize and attack cancer cells. The discovery and development of immune checkpoint inhibitors have been a significant advancement in the field of oncology. Immune checkpoints are molecules on the surface of immune cells and cancer cells that regulate the immune response. They play a crucial role in preventing excessive immune activity and maintaining self-tolerance to prevent autoimmune reactions. Cancer cells can exploit these immune checkpoints to evade detection by the immune system. By interacting with immune checkpoint molecules, cancer cells can essentially "turn off" immune responses that would otherwise target and destroy them. Immune checkpoint inhibitors are drugs designed to block the interactions between immune checkpoint molecules and their corresponding receptors. This "releases the brakes" on the immune system, allowing it to mount a more robust and effective attack against cancer cells. CTLA-4 is expressed on activated T cells and competes with CD28 for binding to B7 molecules on antigen-presenting cells. By blocking this interaction, CTLA-4 inhibitors enhance T cell activation. Immune checkpoint inhibitors have shown remarkable success in treating a variety of cancers, including melanoma, lung cancer, kidney cancer, bladder cancer, and more. Some patients who were previously unresponsive to traditional treatments have achieved long-lasting responses with checkpoint inhibitors. While immune checkpoint inhibitors can be highly effective, they can also lead to immune-related adverse events due to the increased immune activity. These can include inflammation of organs such as the skin, lungs, intestines, and endocrine glands. Predicting which patients will respond to immune checkpoint inhibitors remains a challenge. Biomarkers like PD-L1 expression on tumor cells can provide some guidance, but research is ongoing to identify more accurate predictors of response. Immune checkpoint inhibitors are often used in combination with other cancer therapies, such as chemotherapy, radiation, targeted therapies, and even other immunotherapies. These combinations aim to enhance treatment outcomes by addressing different aspects of cancer growth and immune suppression. This factor will pace up the demand of Global Cancer Vaccines Market.

Increasing Demand of Preventive Vaccines

Cancer preventive vaccines are a type of immunization designed to protect against certain cancers by targeting the viruses or other factors that can lead to the development of those cancers. These vaccines work by stimulating the immune system to recognize and respond to specific infectious agents or antigens associated with cancer development. Human Papillomavirus (HPV) Vaccine is a group of viruses that can lead to various types of cancers, including cervical, anal, oral, and genital cancers. The HPV vaccine targets specific strains of the virus that are most strongly associated with cancer. By vaccinating individuals before they are exposed to HPV, the vaccine can significantly reduce the risk of developing HPV-related cancers. Chronic infection with the hepatitis B virus (HBV) is a major risk factor for liver cancer. The hepatitis B vaccine helps prevent HBV infection, reducing the likelihood of developing liver cancer because of chronic infection. Researchers are actively working on developing vaccines to prevent other types of cancers. For example, vaccines targeting the Epstein-Barr virus (EBV) are being explored to potentially prevent certain types of lymphomas and other cancers associated with EBV. This factor will accelerate the demand of Global Cancer Vaccines Market.

Advancements in Cancer Vaccine Technology

Advancements in cancer vaccine technology have significantly impacted the development, design, and effectiveness of cancer vaccines. Neoantigens are unique proteins present on the surface of cancer cells due to mutations. These mutations can be specific to each patient's tumor. Advanced genomic and computational technologies have enabled the identification of neoantigens, allowing for the design of personalized cancer vaccines that target these unique markers. The development of mRNA vaccine technology, as seen with COVID-19 vaccines, has also impacted cancer vaccine research. mRNA vaccines can be designed to encode specific tumor antigens, enabling the immune system to recognize and target cancer cells. This approach provides a rapid and flexible platform for vaccine development. Viral vectors, such as adenoviruses, can be engineered to carry genetic material encoding tumor antigens. These vectors deliver genetic information into cells, triggering an immune response against cancer cells expressing the antigen. Peptide vaccines consist of short sequences of amino acids that correspond to specific tumor antigens. Advances in peptide synthesis and delivery methods have improved the effectiveness of these vaccines. Dendritic cells play a critical role in initiating immune responses. Dendritic cell vaccines involve isolating a patient's dendritic cells, loading them with tumor antigens, and then reinfusing them into the patient. This primes the immune system to target cancer cells. Nanoparticles can serve as delivery vehicles for vaccine components, enhancing their stability, targeting, and uptake by immune cells. Nanotechnology also offers the potential to improve the presentation of antigens to the immune system. Some cancer vaccines are designed to modify the tumor microenvironment to make it more conducive to an effective immune response. This can involve targeting immunosuppressive factors or promoting the recruitment of immune cells to the tumor site. Adjuvants are substances added to vaccines to enhance the immune response. Advances in adjuvant technology have led to the development of more effective formulations that can stimulate a stronger and longer-lasting immune response. This factor will help in the development of Global Cancer Vaccines Market.


Download Free Sample Report

Key Market Challenges

Complexity of Cancer Immunology

Cancer immunology involves the intricate interplay between cancer cells and the immune system, and understanding and manipulating this interaction for therapeutic purposes is no small task. Cancers are highly heterogeneous, meaning that they can have diverse populations of cells with distinct genetic and antigenic profiles. Identifying the right antigens to target with a vaccine becomes challenging, as a one-size-fits-all approach may not be effective. Cancer cells can develop mechanisms to evade immune detection and attack. They can downregulate antigens, express inhibitory molecules, or create an immunosuppressive microenvironment. Developing vaccines that overcome these strategies is complex. Selecting the most appropriate antigens for targeting is a challenge. Not all tumor antigens are equally effective at inducing a strong immune response, and the wrong choice can result in inadequate therapeutic outcomes. The immune system is designed to avoid attacking healthy cells. Overcoming immune tolerance mechanisms while avoiding autoimmune reactions is a delicate balance that must be considered in vaccine design. Ensuring that the vaccine itself is immunogenic and can stimulate a robust immune response is crucial. Some tumors may have a suppressive effect on the immune system, making it difficult to generate a response. Identifying reliable biomarkers that predict which patients will respond positively to a cancer vaccine is a challenge. Responders and non-responders can have varied immune profiles, and finding consistent predictive markers can be difficult.

Identification of Appropriate Targets

The success of a cancer vaccine heavily depends on selecting the right antigens to stimulate an effective immune response against the tumor while minimizing off-target effects. Tumor-specific antigens are unique to cancer cells and not present on normal cells. Identifying these antigens can be challenging as they can vary widely among different patients and tumor types. Some tumor antigens are shared between cancer cells and normal cells, albeit at different levels. The immune system might not recognize these antigens as foreign, leading to a weak immune response. Tumors are genetically diverse, resulting in a wide variety of antigens that can be potentially targeted. Selecting the most appropriate antigens that are present in many cancer cells poses a challenge. Tumors are often composed of different cell populations with varying antigen profiles. Identifying antigens that are common across these populations can be difficult. Some tumor antigens might change over time due to tumor evolution, making it necessary to monitor and adjust vaccine targets accordingly. Identifying antigens that stimulate a strong immune response against cancer cells without triggering autoimmune reactions against normal tissues is crucial.

Key Market Trends

Collaborations and Partnerships

The complex nature of cancer research, vaccine development, and clinical trials often necessitates collaboration among various stakeholders to accelerate progress, share expertise, and pool resources. Developing effective cancer vaccines requires expertise in various fields, including immunology, oncology, virology, genetics, and more. Collaborations allow researchers and organizations to bring together experts from different disciplines to tackle complex challenges. Collaborations enable the sharing of resources, such as research facilities, laboratories, equipment, and reagents. This can reduce costs and accelerate the research and development process. Partnerships provide access to cutting-edge technologies and platforms that individual organizations might not have. This can streamline vaccine development and improve research capabilities. In-depth understanding of cancer biology and immunology requires access to vast amounts of data. Collaborations allow for data sharing, analysis, and integration, facilitating better insights into vaccine targets and mechanisms. Running clinical trials for cancer vaccines often requires collaboration among multiple institutions and hospitals. Partnerships can facilitate patient recruitment, trial logistics, and data collection. Collaborations can attract funding from various sources, including government agencies, private investors, philanthropic organizations, and venture capital firms. This financial support can drive research and development efforts. Partnerships with pharmaceutical companies can help bring cancer vaccines to market more effectively, leveraging established distribution channels, sales teams, and marketing resources.

Segmental Insights

Vaccine Type Insights

In 2022, the Cancer Vaccines market was dominated by the preventive vaccine segment with overall revenue of 53.88% in 2022 and is predicted to continue expanding over the coming years. Viral infections can lead to a variety of malignancies, and preventive vaccination is an important factor in reducing the risk. Vaccines against the Human Papillomavirus (HPV) and Hepatitis B virus have been associated with a decrease in the incidence of viral-related cancers, including cervical cancer and liver cancer. In January, it was reported that HPV vaccination resulted in a 65% reduction in cervical cancer cases among women between the ages of 20 and 24 between 2012 and 2019.

Indication Type Insights

In 2022, the Cancer Vaccines market was dominated by cervical cancer segment with a share of around 29.79% in 2022 and is predicted to continue expanding over the coming years. C The segment’s growth can be attributed to the increasing incidence of cervical cancer. The World Health Organization (WHO) reports that cervical cancer is the 4th most common cancer among women, with an estimated 604,907 cases diagnosed in 2020. Furthermore, the growing awareness of the prevention and eradication of cervical cancer can also contribute to the growth of the market.

Technology Type Insights

In 2022, the Cancer Vaccines market was dominated by recombinant vaccine segment with a share of around 56.48% in 2022 and is predicted to continue expanding over the coming years. These are the most widely available vaccines available on the market. Major players in the market possess vaccines created through the utilization of recombinant technology. The viral vector and DNA cancer vaccines segment is expected to register the fastest CAGR over the forecast period. The segment growth is attributed to the extensive adoption of viral vectors for vaccine development.


Download Free Sample Report

Regional Insights

The North America region has established itself as the leader in the Global Cancer Vaccines Market with a share of around 35.29% in 2022. The growth of the market in the region can be attributed to the growing burden of cancer, increasing R&D, and an expanding healthcare system in the region. According to the Centers for Disease Control and Prevention (CDC), in 2020, the number of new cancer cases in the United States reached 1,603.844, resulting in the death of approximately 602, 347 people due to cancer.

Recent Developments

  • In October 2022, Phase II clinical trials of Anxia Bioscience’s preventive breast cancer vaccine was initiated. The clinical trial was funded by an U.S. Department of Defense grant.
  • In September 2022, India's domestic vaccine, CERVAVAC, has been officially launched by the Union Minister of State for Science and Technology, with the aim of preventing cervical cancer.
  • In June 2023, The Asia-Pacific Women’s Cancer Coalition (AWC) is a collaborative effort between Crowley & Moring International (CMO), Roche (Roche), TogetHER (TherapeHER for Health), CAPED (CAPED) and Jhpiega (Jhpiego) to bring attention to the increasing incidence of breast and cervical cancers in Asia-Pacific. The coalition will identify opportunities and close the gaps to help countries reach their national goals in terms of cancer prevention and cancer control through transformative public-private partnerships and best practice sharing for policy actions, particularly around the adoption of cutting-edge technologies for screening, early detection, and disease management.
  • In July 2023, the first domestic vaccine against cervical cancer has been released by the Serum Institute. On January 24, the Union Home Minister, Mr. Amit Shah, launched the first indigenous Human Papillomavirus (HPV) vaccine in the presence of the Chief Executive Officer (CEO) of the SII, Dr. Adar Punawalla, and the Director of the Government and Regulatory Affairs of SII, Mr. Prakash Kumar Sing.

Key Market Players

  • Merck & Co., Inc.
  • GSK plc
  • Dendreon Pharmaceuticals LLC.
  • Dynavax Technologies.
  • Ferring B.V.
  • Amgen, Inc.
  • Moderna, Inc.
  • Sanofi SA
  • AstraZeneca Pharmaceuticals LP
  • Bristol-Myers Squibb Company

 

 By Indication Type

 By Vaccine Type

By Technology Type

By Region
  • Prostate Cancer
  • Melanoma
  • Bladder Cancer
  • Cervical Cancer
  • Preventive Cancer Vaccines
  • Therapeutic Cancer Vaccines
  • Recombinant Cancer Vaccines
  • Whole-Cell Cancer Vaccines
  • Viral Vector And DNA Cancer Vaccines
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • South America

 

 

Report Scope:

In this report, the Global Cancer Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Cancer Vaccine Market, By Indication Type:

o    Prostate Cancer

o    Melanoma

o    Bladder Cancer

o    Cervical Cancer

  • Cancer Vaccine Market, By Vaccine Type:

o   Preventive Cancer Vaccines

o    Therapeutic Cancer Vaccines

  • Cancer Vaccine Market, By Technology Type:

o   Recombinant Cancer Vaccines

o   Whole-Cell Cancer Vaccines

o   Viral Vector and DNA Cancer Vaccines

  • Global Cancer Vaccine Market, By region:

o   North America

§  United States

§  Canada

§  Mexico

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Australia

§  Japan

o   Europe

§  Germany

§  France

§  United Kingdom

§  Spain

§  Italy

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cancer Vaccine Market.

Available Customizations:

Global Cancer Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Cancer Vaccine Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Voice of Customer

5.       Clinical Trials Analysis

5.1.    Ongoing Clinical Trials

5.2.    Completed Clinical Trials

5.3.    Terminated Clinical Trials

5.4.    Breakdown of Pipeline, By Development Phase

5.5.    Breakdown of Pipeline, By Status

5.6.    Breakdown of Pipeline, By Study Type

5.7.    Breakdown of Pipeline, By Region

5.8.    Clinical Trials Heat Map

6.    Global Cancer Vaccine Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Indication Type (Prostate Cancer, Melanoma, Bladder Cancer, Cervical Cancer

6.2.2.     By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines)

6.2.3.     By Technology Type (Recombinant Cancer Vaccines, Whole-Cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines)

6.2.4.     By Company (2022)

6.2.5.     By Region

6.3.  Market Map

7.    North America Cancer Vaccine Market Outlook

7.1.  Market Size & Forecast   

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Indication Type

7.2.2.     By Vaccine Type

7.2.3.     By Technology Type

7.2.4.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Cancer Vaccine Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Indication Type

7.3.1.2.2.             By Vaccine Type

7.3.1.2.3.             By Technology Type

7.3.2.     Mexico Cancer Vaccine Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Indication Type

7.3.2.2.2.             By Vaccine Type

7.3.2.2.3.             By Technology Type

7.3.3.     Canada Cancer Vaccine Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Indication Type

7.3.3.2.2.             By Vaccine Type

7.3.3.2.3.             By Technology Type

8.    Europe Cancer Vaccine Market Outlook

8.1.  Market Size & Forecast   

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Indication Type

8.2.2.     By Vaccine Type

8.2.3.     By Technology Type

8.2.4.     By Country

8.3.  Europe: Country Analysis

8.3.1.     France Cancer Vaccine Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Indication Type

8.3.1.2.2.             By Vaccine Type

8.3.1.2.3.             By Technology Type

8.3.2.     Germany Cancer Vaccine Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Indication Type

8.3.2.2.2.             By Vaccine Type

8.3.2.2.3.             By Technology Type

8.3.3.     United Kingdom Cancer Vaccine Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Indication Type

8.3.3.2.2.             By Vaccine Type

8.3.3.2.3.             By Technology Type

8.3.4.     Italy Cancer Vaccine Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Indication Type

8.3.4.2.2.             By Vaccine Type

8.3.4.2.3.             By Technology Type

8.3.5.     Spain Cancer Vaccine Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Indication Type

8.3.5.2.2.             By Vaccine Type

8.3.5.2.3.             By Technology Type

9.    Asia-Pacific Cancer Vaccine Market Outlook

9.1.  Market Size & Forecast   

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Indication Type

9.2.2.     By Vaccine Type

9.2.3.     By Technology Type

9.2.4.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     China Cancer Vaccine Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Indication Type

9.3.1.2.2.             By Vaccine Type

9.3.1.2.3.             By Technology Type

9.3.2.     India Cancer Vaccine Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Indication Type

9.3.2.2.2.             By Vaccine Type

9.3.2.2.3.             By Technology Type

9.3.3.     South Korea Cancer Vaccine Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Indication Type

9.3.3.2.2.             By Vaccine Type

9.3.3.2.3.             By Technology Type

9.3.4.     Japan Cancer Vaccine Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Indication Type

9.3.4.2.2.             By Vaccine Type

9.3.4.2.3.             By Technology Type

9.3.5.     Australia Cancer Vaccine Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Indication Type

9.3.5.2.2.             By Vaccine Type

9.3.5.2.3.             By Technology Type

10.  South America Cancer Vaccine Market Outlook

10.1.    Market Size & Forecast

10.1.1.  By Value

10.2.    Market Share & Forecast

10.2.1.  By Indication Type

10.2.2.  By Vaccine Type

10.2.3.  By Technology Type

10.2.4.  By Country

10.3.    South America: Country Analysis

10.3.1.  Brazil Cancer Vaccine Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Indication Type

10.3.1.2.2.           By Vaccine Type

10.3.1.2.3.           By Technology Type

10.3.2.  Argentina Cancer Vaccine Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Indication Type

10.3.2.2.2.           By Vaccine Type

10.3.2.2.3.           By Technology Type

10.3.3.  Colombia Cancer Vaccine Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Indication Type

10.3.3.2.2.           By Vaccine Type

10.3.3.2.3.           By Technology Type

11.  Middle East and Africa Cancer Vaccine Market Outlook

11.1.    Market Size & Forecast

11.1.1.  By Value

11.2.    Market Share & Forecast

11.2.1.  By Indication Type

11.2.2.  By Vaccine Type

11.2.3.  By Technology Type

11.2.4.  By Country

11.3.    MEA: Country Analysis

11.3.1.  South Africa Cancer Vaccine Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Indication Type

11.3.1.2.2.           By Vaccine Type

11.3.1.2.3.           By Technology Type

11.3.2.  Saudi Arabia Cancer Vaccine Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Indication Type

11.3.2.2.2.           By Vaccine Type

11.3.2.2.3.           By Technology Type

11.3.3.  UAE Cancer Vaccine Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Indication Type

11.3.3.2.2.           By Vaccine Type

11.3.3.2.3.           By Technology Type

12.  Market Dynamics

12.1.    Drivers

12.2.    Challenges

13.  Market Trends & Developments

13.1.    Recent Developments

13.2.    Product Launches

13.3.    Mergers & Acquisitions

14.  PESTLE Analysis

15.  Porter’s Five Forces Analysis

15.1.    Competition in the Industry

15.2.    Potential of New Entrants

15.3.    Power of Suppliers

15.4.    Power of Customers

15.5.    Threat of Substitute Product

16.  Competitive Landscape

16.1.    Business Overview

16.2.    Company Snapshot

16.3.    Products & Services

16.4.    Financials (In case of listed companies)

16.5.    Recent Developments

16.6.    SWOT Analysis

           16.6.1.  Merck & Co., Inc.

           16.6.2.  GSK plc

           16.6.3.  Dendreon Pharmaceuticals LLC.

           16.6.4.  Dynavax Technologies.

           16.6.5.  Ferring B.V.

           16.6.6.  Amgen, Inc.

           16.6.7.  Moderna, Inc.

           16.6.8.  Sanofi SA

           16.6.9.  AstraZeneca Pharmaceuticals LP

           16.6.10. Bristol-Myers Squibb Company

17. Strategic Recommendations

18. About us  & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Dyes Market was estimated to be USD 7.55 Billion in 2022.

down-arrow

GSK plc, Dendreon Pharmaceuticals LLC., Dynavax Technologies., Ferring B.V., Amgen, Inc., Moderna, Inc. are some of the key players operating in the Global Cancer Vaccine Market.

down-arrow

Finding suitable tumor antigens (targets for the immune system) that are unique to cancer cells and not present on healthy cells is crucial. Identifying these targets accurately and efficiently is a challenge that affects the efficacy of cancer vaccines.

down-arrow

Advancements in genomics and immunotherapy have led to the development of personalized cancer vaccines. These vaccines are tailored to target specific mutations present in an individual's tumor, enhancing their effectiveness and minimizing side effects.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Cancer Vaccines Market to be dominated by North America Region through 2028

Nov, 2023

Rising cases of Cervical Cancer and initiatives taken by the government are the major drivers for the Global Cancer Vaccines Market.

Why Choose Us